| Is elevated resting heart rate an independent predictor of cardiovascular disease? A report from the National FINRISK Study. | M T Cooney (Dublin, IE) | Epidemiology & prevention | 30 Aug 2009 |
| Resting heart rate remains a risk factor for CardioVascular (CV) and non-CardioVascular (non-CV) mortality in healthy subjects after adjusting for inflammatory markers. The Copenhagen city heart study. | M T Jensen (Copenhagen, DK) | Epidemiology & prevention | 30 Aug 2009 |
| Increased exercise capacity is associated with lower mortality risk in men 70 years and older. | P Kokkinos (Washington, US) | Epidemiology & prevention | 30 Aug 2009 |
| Adipokines and coronary heart disease - results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. | M Karakas (Ulm, DE) | Epidemiology & prevention | 30 Aug 2009 |
| Respective contribution of carotid intima-media thickness and plaques to incident coronary heart disease in community-dwelling elderly. The three-city study. | M Plichart (Paris, FR) | Epidemiology & prevention | 30 Aug 2009 |
| Uric acid: an underestimated cardiovascular risk factor. | G Levantesi (Vasto, IT) | Epidemiology & prevention | 30 Aug 2009 |
| Population approach in coronary prevention: the method of choice. Pro. | T Jorgensen (Glostrup, DK) | Epidemiology & prevention | 30 Aug 2009 |
| Population approach in coronary prevention: the method of choice: Contra. | G De Backer (Ghent, BE) | Epidemiology & prevention | 30 Aug 2009 |
| Population versus high-risk approach in cardiovascular prevention. Conclusion. | C M van Duijn (Rotterdam, NL) | Epidemiology & prevention | 30 Aug 2009 |
| Genetic screening of coronary predisposition is coming to clinical practice: Pro. | H Schunkert (Lubeck, DE) | Epidemiology & prevention | 30 Aug 2009 |
| Genetic screening of coronary predisposition is coming to clinical practice: Contra. | C M van Duijn (Rotterdam, NL) | Epidemiology & prevention | 30 Aug 2009 |
| Genetic screening of coronary predisposition is coming to clinical practice: Pro. | H Schunkert (Lubeck, DE) | Epidemiology & prevention | 30 Aug 2009 |
| Genetic screening of coronary predisposition is coming to clinical practice: Contra. | C M van Duijn (Rotterdam, NL) | Epidemiology & prevention | 30 Aug 2009 |
| Population versus high-risk approach in cardiovascular prevention: Conclusion. | C M van Duijn (Rotterdam, NL) | Epidemiology & prevention | 30 Aug 2009 |
| Randomised controlled trial of low dose aspirin in the prevention of cardiovascular events and death in subjects with asymptomatic atherosclerosis.: Discussant. | C Patrono (Rome, IT) | Epidemiology & prevention | 30 Aug 2009 |
| A randomized comparison of a clopidogrel high loading and maintenance dose regimen versus standard dose and high versus low dose aspirin in 25,000 patients with acute coronary syndromes: Results of the CURRENT OASIS 7 Trial. | S R Mehta (Hamilton, CA) | Ischaemia / ACS / infarction | 30 Aug 2009 |
| CURRENT OASIS 7: Discussant. | F Van de Werf (Leuven, BE) | Ischaemia / ACS / infarction | 30 Aug 2009 |
| Comparison of Ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: results of the PLATelet inhibition and patient Outcomes (PLATO) trial. | L C Wallentin (Uppsala, SE) | Ischaemia / ACS / infarction | 30 Aug 2009 |
| PLATO: Discussant. | S D Kristensen (Aarhus N, DK) | Ischaemia / ACS / infarction | 30 Aug 2009 |
| A randomized trial of dabigatran, a oral direct thrombin inhibitor, compared to warfarin in 18,113 patients with atrial fibrillation at high risk of stroke. | S J Connolly (Hamilton, CA) | Arrhythmias / Pacing / Resynchronisation | 30 Aug 2009 |
| A randomized trial of dabigatran, a oral direct thrombin inhibitor, compared to warfarin in 18,113 patients with atrial fibrillation at high risk of stroke.: Discussant. | A J Camm (London, GB) | Arrhythmias / Pacing / Resynchronisation | 30 Aug 2009 |
| Clinical Efficacy and Safety of Otamixaban, an Intravenous, Selective Factor Xa Inhibitor for the Treatment of Non-ST-Elevation Acute Coronary Syndromes: Results of SEPIA-ACS1 TIMI 42. | M Sabatine (Boston, US) | Ischaemia / ACS / infarction | 30 Aug 2009 |
| SEPIA-ACS1 TIMI 42: Discussant. | H D White (Auckland, NZ) | Ischaemia / ACS / infarction | 30 Aug 2009 |
| Genetics of inflammation and atherosclerosis. | H Schunkert (Lubeck, DE) | Vascular biology | 30 Aug 2009 |
| Inflammatory biomarkers and therapeutic implications. | A C Newby (Bristol, UK) | Vascular biology | 30 Aug 2009 |
| Endocarditis: coping with the Guidelines: Panel discussion. | P Tornos Mas (Barcelona, ES), G Habib (Marseille, FR), R Dion (GENK, BE) | Valvular disease | 30 Aug 2009 |
| A patient with persisting fever. | A Vahanian (Paris, FR) | Valvular disease | 30 Aug 2009 |
| Endocarditis: coping with the Guidelines: Panel discussion. | R Dion (GENK, BE), G Habib (Marseille, FR), P Tornos Mas (Barcelona, ES) | Valvular disease | 30 Aug 2009 |
| Endocarditis: coping with the Guidelines: What do the guidelines tell us? | A Vahanian (Paris, FR) | Valvular disease | 30 Aug 2009 |
| A deteriorating patient despite appropriate initial treatment choices. | J L Vachiery (Brussels, BE) | Pulmonary circulation | 30 Aug 2009 |
| A young lady who is improving but not enough. | N Galie (Bologna, IT) | Pulmonary circulation | 30 Aug 2009 |
| What do the Guidelines say? | N Galie (Bologna, IT) | Pulmonary circulation | 30 Aug 2009 |
| Treating dyslipidemia. How aggressive should we be? Case 1. | U Landmesser (Zurich, CH) | Epidemiology & prevention | 30 Aug 2009 |
| Treating dyslipidemia. How aggressive should we be? Case 2. | J E Deanfield (London, GB) | Epidemiology & prevention | 30 Aug 2009 |
| What do the Guidelines say? | I M Graham (Dublin, IE) | Epidemiology & prevention | 30 Aug 2009 |
| ESC Guidelines on the prevention, diagnosis and treatment of infective endocarditis. | G Habib (Marseille, FR) | Valvular disease | 30 Aug 2009 |
| ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. | N Galie (Bologna, IT) | Pulmonary circulation | 30 Aug 2009 |
| ESC Guidelines for preoperative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. | D Poldermans (Rotterdam, NL) | Peripheral circulation/Stroke | 30 Aug 2009 |
| ESC Guidelines for the management of syncope. | A Moya I Mitjans (Barcelona, ES) | Arrhythmias / Pacing / Resynchronisation | 30 Aug 2009 |
| Risk stratification and diagnostic strategy in patients with syncope. | A Moya I Mitjans (Barcelona, ES) | Arrhythmias / Pacing / Resynchronisation | 30 Aug 2009 |
| Syncope unit: utopia or a necessity. | M Brignole (Lavagna, IT) | Arrhythmias / Pacing / Resynchronisation | 30 Aug 2009 |
| Specific aspects of syncope in the elderly: a growing problem. | A Ungar (Firenze, IT) | Arrhythmias / Pacing / Resynchronisation | 30 Aug 2009 |
| Future directions in diagnosis and management of syncope. | D G Benditt (Minneapolis, US) | Arrhythmias / Pacing / Resynchronisation | 30 Aug 2009 |
| Defining and managing advanced heart failure. | A Fucili (Ferrara, IT) | Heart failure / LV dysfunction | 30 Aug 2009 |
| Lessons from the INTERMACS registry. | K Dickstein (Stavanger, NO) | Heart failure / LV dysfunction | 30 Aug 2009 |
| Surgical interventions and short-term devices. | A Pitsis (Thessaloniki, GR) | Heart failure / LV dysfunction | 30 Aug 2009 |
| Long-term devices and the artificial heart. | S Westaby (Oxford, GB) | Heart failure / LV dysfunction | 30 Aug 2009 |
| Circulating endothelial progenitor cells and acute myocardial infarction. | S Dimmeler (Frankfurt, DE) | Cardiovascular system (patho)physiology | 30 Aug 2009 |
| Pretreatment of stem cells and recipient tissues. | K Lunde (Oslo, NO) | Cardiovascular system (patho)physiology | 30 Aug 2009 |
| Cardiac stem cells. | D Torella (Catanzaro, IT) | Cardiovascular system (patho)physiology | 30 Aug 2009 |
| C-reactive protein and other plasma markers, of incremental value in risk prediction. | W Koenig (Ulm, DE) | Cardiac cellular biology | 30 Aug 2009 |
| The endothelial surface layer/glycocalyx: an emerging player in vascular health and disease. | H Vink (Maastricht, NL) | Cardiac cellular biology | 30 Aug 2009 |
| The impact of early diet and interventions on the vasculature in animal models. | C Torrens (Southampton, GB) | Cardiac cellular biology | 30 Aug 2009 |
| Impact of endothelial dysfunction on atherosclerosis development in childhood. | P Leeson (Oxford, GB) | Cardiac cellular biology | 30 Aug 2009 |
| B-CONVINCED. Beta-blocker CONtinuation Versus INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. | G Jondeau (Paris, FR) | Heart failure / LV dysfunction | 30 Aug 2009 |
| B-CONVINCED: Discussant. | K Swedberg (Goteborg, SE) | Heart failure / LV dysfunction | 30 Aug 2009 |
| BEAUTIFUL: Discussant. | M Boehm (Homburg/Saar, DE) | Pharmacology and pharmacotherapy | 30 Aug 2009 |
| Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. | A P Maggioni (Florence, IT) | Arrhythmias / Pacing / Resynchronisation | 30 Aug 2009 |
| GISSI-HF: Discussant. | HJGM Crijns (Maastricht, NL) | Arrhythmias / Pacing / Resynchronisation | 30 Aug 2009 |
| Heart failure events assessment in the Rosiglitazone Evaluation for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD). | M Komajda (Paris, FR) | Heart failure / LV dysfunction | 30 Aug 2009 |
| Characteristics of patients enrolled in the Predictors of Response to CRT (PROSPECT) trial: comparison of subgroups according to extent of LV reverse remodeling. | RJ van Bommel (Leiden, NL) | Arrhythmias / Pacing / Resynchronisation | 30 Aug 2009 |
| PROSPECT: Discussant. | C Linde (Stockholm, SE) | Arrhythmias / Pacing / Resynchronisation | 30 Aug 2009 |
| Cardiac Resynchronization Therapy Induces Major Structural and Functional Reverse Remodeling In Mild Heart Failure. 24 month results of the REVERSE trial. | S Ghio (Pavia, IT) | Arrhythmias / Pacing / Resynchronisation | 30 Aug 2009 |
| REVERSE: Discussant. | J G F Cleland (Kingston upon Hull, GB) | Arrhythmias / Pacing / Resynchronisation | 30 Aug 2009 |
| Prehospital challenges. | P M Clemmensen (Copenhagen, DK) | Ischaemia / ACS / infarction | 30 Aug 2009 |
| Evolving strategies for reperfusion therapy. | N Danchin (Paris, FR) | Ischaemia / ACS / infarction | 30 Aug 2009 |
| Optimal antithrombotic therapy. | L C Wallentin (Uppsala, SE) | Ischaemia / ACS / infarction | 30 Aug 2009 |
| Late-comers: which options? | A Abbate (Richmond, US) | Ischaemia / ACS / infarction | 30 Aug 2009 |